On August 5, 2026 Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, reported that IP Australia has issued a notice of acceptance in respect of the Company’s Australian patent application no. 2019365135 (the "Patent Application").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Patent Application entitled "Antibody Library and Method", covers two families of antibodies, and the methods for designing such antibody libraries. The patent, once granted, is expected to be complementary to Fusion’s offering to provide "Opti" designed antibody libraries for a range of applications including: Antibody Discovery; Affinity Maturation; and Sequence Optimisation.

The Company continues to progress additional patent applications in respect of the OptiMAL Library in several other territories worldwide including Europe and China.

Receipt of a notice of acceptance indicates that the claims in the Patent Application are patentable and does not in itself represent a grant of patent rights. Fusion anticipates that the patent will be granted in due course, following completion of certain administrative requirements, including payment of the applicable fees, and the successful completion of a three-month gazetting period.

(Press release, Fusion Antibodies, AUG 5, 2026, View Source [SID1234669754])